Amedeo Smart

Free Medical Literature Service



Gastric Cancer

  Free Subscription

Articles published in
    August 2021
  1. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    >> Share

    July 2021
  2. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    >> Share

  3. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    >> Share

    May 2021
  4. SUNDAR R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, et al
    Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
    Gut. 2021 May 12. pii: gutjnl-2021-324060. doi: 10.1136/gutjnl-2021-324060.
    >> Share

  5. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    >> Share

  6. LEE JWJ, Zhu F, Srivastava S, Tsao SK, et al
    Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
    Gut. 2021 May 11. pii: gutjnl-2021-324057. doi: 10.1136/gutjnl-2021-324057.
    >> Share

    February 2021
    Gastric biopsies in the assessment and management of patients at risk of gastric adenocarcinoma.
    Gut. 2021;70:431-432.
    >> Share

  8. CHEN R, Liu Y, Song G, Li B, et al
    Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study.
    Gut. 2021;70:251-260.
    >> Share

  9. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.
    >> Share

    January 2021
  10. AJANI JA, Xu Y, Huo L, Wang R, et al
    YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition.
    Gut. 2021;70:55-66.
    >> Share

    November 2020
  11. SUNDAR R, Liu DH, Hutchins GG, Slaney HL, et al
    Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.
    Gut. 2020 Nov 23. pii: gutjnl-2020-320805. doi: 10.1136/gutjnl-2020-320805.
    >> Share

    October 2020
  12. SO JBY, Kapoor R, Zhu F, Koh C, et al
    Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322065. doi: 10.1136/gutjnl-2020-322065.
    >> Share

  13. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    >> Share

  14. MARCOS P, Brito-Goncalves G, Libanio D, Pita I, et al
    Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?
    Gut. 2020;69:1762-1768.
    >> Share

  15. KRISHNAN V, Lim DXE, Hoang PM, Srivastava S, et al
    DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.
    Gut. 2020;69:1738-1749.
    >> Share

    September 2020
  16. DIXON K, Senz J, Kaurah P, Huntsman DG, et al
    Rare APC promoter 1B variants in gastric cancer kindreds unselected for fundic gland polyposis.
    Gut. 2020 Sep 7. pii: gutjnl-2020-321990. doi: 10.1136/gutjnl-2020-321990.
    >> Share

  17. BANKS M, Uedo N, Bhandari P, Gotoda T, et al
    EMR achieves similar oncological outcomes as ESD for gastric neoplasia of <1cm, requiring less expertise, training and time.
    Gut. 2020;69:1.
    >> Share

  18. SHAHIDI N, Bourke MJ
    ESD, not EMR, should be the first-line therapy for early gastric neoplasia.
    Gut. 2020;69:1-2.
    >> Share

  19. GHISA M, Rugge M, Fassan M, Farinati F, et al
    There is much more to rely on histology than the sole endoscopy tells us.
    Gut. 2020;69:1.
    >> Share

    August 2020
  20. MURAKAMI D, Yamato M, Amano Y, Tada T, et al
    Challenging detection of hard-to-find gastric cancers with artificial intelligence-assisted endoscopy.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322453. doi: 10.1136/gutjnl-2020-322453.
    >> Share

  21. CHIANG TH, Chang WJ, Chen SL, Yen AM, et al
    Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands.
    Gut. 2020 Aug 13. pii: gutjnl-2020-322200. doi: 10.1136/gutjnl-2020-322200.
    >> Share

    June 2020
  22. ARNOLD M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I, et al
    Global burden of oesophageal and gastric cancer by histology and subsite in 2018.
    Gut. 2020 Jun 30. pii: gutjnl-2020-321600. doi: 10.1136/gutjnl-2020-321600.
    >> Share

  23. BORNSCHEIN J, Rugge M
    Bright future for endoscopy: the new frontier of gastric cancer secondary prevention.
    Gut. 2020 Jun 12. pii: gutjnl-2020-321570. doi: 10.1136/gutjnl-2020-321570.
    >> Share

  24. HATTA W, Tsuji Y, Yoshio T, Kakushima N, et al
    Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score.
    Gut. 2020 Jun 4. pii: gutjnl-2019-319926. doi: 10.1136/gutjnl-2019-319926.
    >> Share

  25. OOI WF, Nargund AM, Lim KJ, Zhang S, et al
    Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma.
    Gut. 2020;69:1039-1052.
    >> Share

    April 2020
  26. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    >> Share

  27. YOSHIDA N, Doyama H, Yano T, Horimatsu T, et al
    Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging.
    Gut. 2020 Apr 2. pii: gutjnl-2019-319631. doi: 10.1136/gutjnl-2019-319631.
    >> Share

    March 2020
  28. FORD AC, Yuan Y, Moayyedi P
    Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.
    Gut. 2020 Mar 23. pii: gutjnl-2020-320839. doi: 10.1136/gutjnl-2020-320839.
    >> Share

  29. KOLB JM, Leong S, Westbrook LM, Patel SG, et al
    Aggressive case of early onset gastric cancer; identifying the knowledge gap.
    Gut. 2020 Mar 11. pii: gutjnl-2019-320453. doi: 10.1136/gutjnl-2019-320453.
    >> Share

  30. YAMAJI Y, Hirata Y
    Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
    Gut. 2020;69:605-606.
    >> Share

    February 2020
  31. MAEDA M, Takeshima H, Iida N, Hattori N, et al
    Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3.
    Gut. 2020;69:243-251.
    >> Share

    January 2020
  32. ARNOLD M, Park JY, Camargo MC, Lunet N, et al
    Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035.
    Gut. 2020 Jan 30. pii: gutjnl-2019-320234. doi: 10.1136/gutjnl-2019-320234.
    >> Share

  33. DING L, Li Q, Chakrabarti J, Munoz A, et al
    MiR130b from Schlafen4(+) MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer.
    Gut. 2020 Jan 24. pii: gutjnl-2019-318817. doi: 10.1136/gutjnl-2019-318817.
    >> Share

  34. ERAWIJANTARI PP, Mizutani S, Shiroma H, Shiba S, et al
    Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles.
    Gut. 2020 Jan 16. pii: gutjnl-2019-319188. doi: 10.1136/gutjnl-2019-319188.
    >> Share

  35. GUIMARAES P, Keller A, Fehlmann T, Lammert F, et al
    Deep-learning based detection of gastric precancerous conditions.
    Gut. 2020;69:4-6.
    >> Share

  36. WANG R, Song S, Harada K, Ghazanfari Amlashi F, et al
    Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
    Gut. 2020;69:18-31.
    >> Share

    December 2019
  37. GUO Y, Zhang Y, Gerhard M, Gao JJ, et al
    Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer.
    Gut. 2019 Dec 19. pii: gutjnl-2019-319696. doi: 10.1136/gutjnl-2019-319696.
    >> Share

  38. COSTA L, Corre S, Michel V, Le Luel K, et al
    USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis.
    Gut. 2019 Dec 10. pii: gutjnl-2019-318640. doi: 10.1136/gutjnl-2019-318640.
    >> Share

    October 2019
  39. JANSEN M, Banks M
    Early detection and risk stratification of gastric cancer are likely to be refined with biopsies targeted through high-resolution-enhanced imaging.
    Gut. 2019 Oct 14. pii: gutjnl-2019-319921. doi: 10.1136/gutjnl-2019-319921.
    >> Share

  40. WANG Q, Chen C, Ding Q, Zhao Y, et al
    METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
    Gut. 2019 Oct 3. pii: gutjnl-2019-319639. doi: 10.1136/gutjnl-2019-319639.
    >> Share

    September 2019
  41. LIU K, Qin M, Huang J
    The prescreening tool for gastric cancer in China.
    Gut. 2019 Sep 3. pii: gutjnl-2019-319591. doi: 10.1136/gutjnl-2019-319591.
    >> Share

  42. CHEUNG KS, Leung WK
    Response to letter to the editor by Moayyedi et al.
    Gut. 2019;68:1721-1722.
    >> Share

  43. BANKS M, Graham D, Jansen M, Gotoda T, et al
    British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.
    Gut. 2019;68:1545-1575.
    >> Share

    August 2019
  44. YAN C, Zhu M, Ding Y, Yang M, et al
    Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations.
    Gut. 2019 Aug 5. pii: gutjnl-2019-318760. doi: 10.1136/gutjnl-2019-318760.
    >> Share

    July 2019
  45. LIAO P, Jia F, Teer JK, Knepper TC, et al
    Geographic variation in molecular subtype for gastric adenocarcinoma.
    Gut. 2019;68:1340-1341.
    >> Share

    June 2019
  46. RUGGE M, Sacchi D, Graham DY, Genta RM, et al
    Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging.
    Gut. 2019 Jun 11. pii: gutjnl-2019-319107. doi: 10.1136/gutjnl-2019-319107.
    >> Share

    May 2019
  47. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population.
    Gut. 2019 May 21. pii: gutjnl-2019-319000. doi: 10.1136/gutjnl-2019-319000.
    >> Share

  48. XU C, Ooi WF, Qamra A, Tan J, et al
    HNF4alpha pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer.
    Gut. 2019 May 8. pii: gutjnl-2018-318025. doi: 10.1136/gutjnl-2018-318025.
    >> Share

    April 2019
  49. QUACH DT, Hiyama T, Gotoda T
    Do subjects with mild or moderate atrophic gastritis or intestinal metaplasia confined to the antrum benefit from gastric cancer surveillance?
    Gut. 2019 Apr 27. pii: gutjnl-2019-318720. doi: 10.1136/gutjnl-2019-318720.
    >> Share

  50. DEN HOLLANDER WJ, Holster IL, den Hoed CM, Capelle LG, et al
    Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions.
    Gut. 2019;68:585-593.
    >> Share

    March 2019
  51. CAI Q, Zhu C, Yuan Y, Feng Q, et al
    Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study.
    Gut. 2019 Mar 29. pii: gutjnl-2018-317556. doi: 10.1136/gutjnl-2018-317556.
    >> Share

  52. WANG P, Wang Y, Langley SA, Zhou YX, et al
    Diverse tumour susceptibility in Collaborative Cross mice: identification of a new mouse model for human gastric tumourigenesis.
    Gut. 2019 Mar 6. pii: gutjnl-2018-316691. doi: 10.1136/gutjnl-2018-316691.
    >> Share

    January 2019
  53. LIN C, He H, Liu H, Li R, et al
    Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer.
    Gut. 2019 Jan 19. pii: gutjnl-2018-316324. doi: 10.1136/gutjnl-2018-316324.
    >> Share

  54. LI T, Guo H, Li H, Jiang Y, et al
    MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia.
    Gut. 2019 Jan 11. pii: gutjnl-2017-315318. doi: 10.1136/gutjnl-2017-315318.
    >> Share

  55. RAHN S, Kruger S, Rocken C, Helm O, et al
    Response to: 'Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma'.
    Gut. 2019;68:179-180.
    >> Share

    September 2018
  56. WANG DS, Liu ZX, Lu YX, Bao H, et al
    Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
    Gut. 2018 Sep 29. pii: gutjnl-2018-316522. doi: 10.1136/gutjnl-2018-316522.
    >> Share

    July 2018
  57. CHUANG SC, Lin CC, Peng CY, Huang WH, et al
    Proton pump inhibitors increase the risk of cholecystitis: a population-based case-control study.
    Gut. 2018 Jul 17. pii: gutjnl-2018-316899. doi: 10.1136/gutjnl-2018-316899.
    >> Share

  58. MOAYYEDI P, Veldhuyzen van Zanten SJO, Hookey L, Armstrong D, et al
    Proton pump inhibitors and gastric cancer: association is not causation.
    Gut. 2018 Jul 13. pii: gutjnl-2018-316958. doi: 10.1136/gutjnl-2018-316958.
    >> Share

    May 2018
  59. KOBAYASHI J, Uchida H, Ito J
    Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer development.
    Gut. 2018 May 25. pii: gutjnl-2018-316592. doi: 10.1136/gutjnl-2018-316592.
    >> Share

    April 2018
  60. SEIDLITZ T, Merker SR, Rothe A, Zakrzewski F, et al
    Human gastric cancer modelling using organoids.
    Gut. 2018 Apr 27. pii: gutjnl-2017-314549. doi: 10.1136/gutjnl-2017-314549.
    >> Share

  61. LAI SW, Lai HC, Lin CL, Liao KF, et al
    Proton pump inhibitors and risk of gastric cancer in a case-control study.
    Gut. 2018 Apr 16. pii: gutjnl-2018-316371. doi: 10.1136/gutjnl-2018-316371.
    >> Share

  62. WAN QY, Wu XT, Li N, Du L, et al
    Long-term proton pump inhibitors use and risk of gastric cancer: a meta-analysis of 926 386 participants.
    Gut. 2018 Apr 3. pii: gutjnl-2018-316416. doi: 10.1136/gutjnl-2018-316416.
    >> Share

    March 2018
  63. COOK MB, Coburn SB, Lam JR, Taylor PR, et al
    Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort.
    Gut. 2018;67:418-529.
    >> Share

    February 2018
  64. PENG YC, Huang LR, Lin CL, Hsu WY, et al
    Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD.
    Gut. 2018 Feb 22. pii: gutjnl-2018-316057. doi: 10.1136/gutjnl-2018-316057.
    >> Share

  65. FERREIRA RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, et al
    Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota.
    Gut. 2018;67:226-236.
    >> Share

    January 2018
  66. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population.
    Gut. 2018 Jan 30. pii: gutjnl-2017-315363. doi: 10.1136/gutjnl-2017-315363.
    >> Share

  67. LATERZA L, Scaldaferri F, Gasbarrini A
    Risk factors for gastric cancer: is it time to discard PPIs?
    Gut. 2018 Jan 13. pii: gutjnl-2017-315621. doi: 10.1136/gutjnl-2017-315621.
    >> Share

  68. RUGGE M, Meggio A, Pravadelli C, Barbareschi M, et al
    Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients.
    Gut. 2018 Jan 6. pii: gutjnl-2017-314600. doi: 10.1136/gutjnl-2017-314600.
    >> Share

  69. SUISSA S, Suissa A
    Proton-pump inhibitors and increased gastric cancer risk: time-related biases.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315729. doi: 10.1136/gutjnl-2017-315729.
    >> Share

    December 2017
  70. NIIKURA R, Hayakawa Y, Hirata Y, Yamada A, et al
    Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis.
    Gut. 2017 Dec 22. pii: gutjnl-2017-315710. doi: 10.1136/gutjnl-2017-315710.
    >> Share

  71. SUZUKI H, Matsuzaki J
    Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk.
    Gut. 2017 Dec 15. pii: gutjnl-2017-315698. doi: 10.1136/gutjnl-2017-315698.
    >> Share

    November 2017
  72. GUETA I, Halkin H, Markovits N, Loebstein R, et al
    Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B 12.
    Gut. 2017 Nov 28. pii: gutjnl-2017-315695. doi: 10.1136/gutjnl-2017-315695.
    >> Share

  73. WALDUM HL, Fossmark R
    Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man.
    Gut. 2017 Nov 20. pii: gutjnl-2017-315629. doi: 10.1136/gutjnl-2017-315629.
    >> Share

  74. Erratum: Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids.
    Gut. 2017;66:2012.
    >> Share

    October 2017
  75. CHEUNG KS, Chan EW, Wong AYS, Chen L, et al
    Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.
    Gut. 2017 Oct 31. pii: gutjnl-2017-314605. doi: 10.1136/gutjnl-2017-314605.
    >> Share

    September 2017
  76. CHEN IF, Liu KW, Tang TQ, Wang WL, et al
    An unusual gastric tumour with gastric outlet obstruction.
    Gut. 2017 Sep 28. pii: gutjnl-2017-315087. doi: 10.1136/gutjnl-2017-315087.
    >> Share

  77. YAN C, Zhu M, Huang T, Yu F, et al
    Genome-wide association studies identified loci contribute to phenotypic variance of gastric cancer.
    Gut. 2017 Sep 22. pii: gutjnl-2017-315230. doi: 10.1136/gutjnl-2017-315230.
    >> Share

  78. NOTO JM, Chopra A, Loh JT, Romero-Gallo J, et al
    Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments.
    Gut. 2017 Sep 18. pii: gutjnl-2017-313863. doi: 10.1136/gutjnl-2017-313863.
    >> Share

    August 2017
  79. RAJENDRAN S, Benna C, Monticelli H, Spiro G, et al
    Germline variation of circadian pathway genes and prognosis of gastric cancer patients.
    Gut. 2017 Aug 8. pii: gutjnl-2017-314740. doi: 10.1136/gutjnl-2017-314740.
    >> Share

  80. COKER OO, Dai Z, Nie Y, Zhao G, et al
    Mucosal microbiome dysbiosis in gastric carcinogenesis.
    Gut. 2017 Aug 1. pii: gutjnl-2017-314281. doi: 10.1136/gutjnl-2017-314281.
    >> Share

    June 2017
  81. HUANG LY, Wang X, Cui XF, Li H, et al
    IRTKS is correlated with progression and survival time of patients with gastric cancer.
    Gut. 2017 Jun 24. pii: gutjnl-2016-313478. doi: 10.1136/gutjnl-2016-313478.
    >> Share

  82. MERA RM, Bravo LE, Camargo MC, Bravo JC, et al
    Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial.
    Gut. 2017 Jun 24. pii: gutjnl-2016-311685. doi: 10.1136/gutjnl-2016-311685.
    >> Share

    May 2017
  83. SIERRA JC, Asim M, Verriere TG, Piazuelo MB, et al
    Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis.
    Gut. 2017 May 4. pii: gutjnl-2016-312888. doi: 10.1136/gutjnl-2016-312888.
    >> Share

  84. THOMPSON ED, Zahurak M, Murphy A, Cornish T, et al
    Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
    Gut. 2017;66:794-801.
    >> Share

    April 2017
  85. WANG Z, Dai J, Hu N, Miao X, et al
    Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies.
    Gut. 2017;66:581-587.
    >> Share

    March 2017
  86. ZHANG X, Xu W
    Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway.
    Gut. 2017 Mar 27. pii: gutjnl-2017-313923. doi: 10.1136/gutjnl-2017-313923.
    >> Share

  87. WANG TT, Zhao YL, Peng LS, Chen N, et al
    Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
    Gut. 2017 Mar 8. pii: gutjnl-2016-313075. doi: 10.1136/gutjnl-2016-313075.
    >> Share

    December 2016
  88. MAEDA M, Nakajima T, Oda I, Shimazu T, et al
    High impact of methylation accumulation on metachronous gastric cancer: 5-year follow-up of a multicentre prospective cohort study.
    Gut. 2016 Dec 21. pii: gutjnl-2016-313387. doi: 10.1136/gutjnl-2016-313387.
    >> Share

    October 2016
  89. MALFERTHEINER P, Megraud F, O'Morain CA, Gisbert JP, et al
    Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
    Gut. 2016 Oct 5. pii: gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288.
    >> Share

    September 2016
  90. ZHU S, Soutto M, Chen Z, Peng D, et al
    Helicobacter pylori-induced cell death is counteracted by NF-kappaB-mediated transcription of DARPP-32.
    Gut. 2016 Sep 2. pii: gutjnl-2016-312141. doi: 10.1136/gutjnl-2016-312141.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016